ZA804180B - Medicaments for the treatment of disorders in lipometabolism and their use - Google Patents
Medicaments for the treatment of disorders in lipometabolism and their useInfo
- Publication number
- ZA804180B ZA804180B ZA00804180A ZA804180A ZA804180B ZA 804180 B ZA804180 B ZA 804180B ZA 00804180 A ZA00804180 A ZA 00804180A ZA 804180 A ZA804180 A ZA 804180A ZA 804180 B ZA804180 B ZA 804180B
- Authority
- ZA
- South Africa
- Prior art keywords
- lipometabolism
- medicaments
- disorders
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
- C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19792928485 DE2928485A1 (de) | 1979-07-14 | 1979-07-14 | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA804180B true ZA804180B (en) | 1981-07-29 |
Family
ID=6075715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA00804180A ZA804180B (en) | 1979-07-14 | 1980-07-11 | Medicaments for the treatment of disorders in lipometabolism and their use |
Country Status (10)
Country | Link |
---|---|
US (1) | US4405644A (xx) |
EP (1) | EP0022958A1 (xx) |
JP (1) | JPS5616411A (xx) |
AU (1) | AU544252B2 (xx) |
DE (1) | DE2928485A1 (xx) |
DK (1) | DK302480A (xx) |
ES (1) | ES493327A0 (xx) |
IL (1) | IL60555A0 (xx) |
NO (1) | NO151362C (xx) |
ZA (1) | ZA804180B (xx) |
Families Citing this family (180)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL67417A (en) * | 1982-01-26 | 1989-10-31 | American Cyanamid Co | Antiatherosclerotic substituted ureas,process for their preparation and pharmaceutical compositions containing them |
US4623662A (en) | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
US5003106A (en) * | 1983-07-19 | 1991-03-26 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
IE57775B1 (en) * | 1983-08-22 | 1993-04-07 | Warner Lambert Co | N-(2,6-disubstituted aromatic)-n'-pyridinyl ureas,processes for their production and pharmaceutical compositions comprising the same |
US4689348A (en) * | 1984-08-17 | 1987-08-25 | Dow Chemical Company | Cyanoguanidines useful as animal growth promoting agents |
US4661520A (en) * | 1984-08-17 | 1987-04-28 | The Dow Chemical Company | Cyanoguanidine useful as an animal growth promoting agent |
DE3636190A1 (de) * | 1986-10-24 | 1988-04-28 | Bayer Ag | Verfahren zur herstellung von n,n-diaryl-harnstoffen |
CN1021819C (zh) * | 1988-01-20 | 1993-08-18 | 山之内制药株式会社 | 作为药物有用的双脲衍生物的制备方法 |
US5290814A (en) * | 1988-11-21 | 1994-03-01 | Burroughs Wellcome Co. | Anti-atherosclerotic diaryl compounds |
JPH0395153A (ja) * | 1989-06-15 | 1991-04-19 | Mitsubishi Kasei Corp | ジフェニル尿素誘導体 |
EP0425443A1 (de) * | 1989-10-27 | 1991-05-02 | Ciba-Geigy Ag | Injizierbares parasitizides Mittel |
JPH05310678A (ja) * | 1990-01-22 | 1993-11-22 | Mitsubishi Kasei Corp | 1−フェニルアルキル−3−フェニル尿素誘導体 |
CA2037669A1 (en) * | 1990-03-12 | 1991-09-13 | Noriki Ito | Urea derivatives and salts thereof, pharmaceutical compositions containing the same, and methods for producing the same |
US5258405A (en) * | 1990-03-12 | 1993-11-02 | Yamanouchi Pharmaceutical Co., Ltd. | Urea derivatives and salts thereof in method for inhibiting the ACAT enzyme |
US5162360A (en) * | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
US6133299A (en) * | 1993-02-25 | 2000-10-17 | Warner-Lambert Company | Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds |
US5547966A (en) * | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
JPH11503110A (ja) * | 1995-02-17 | 1999-03-23 | スミスクライン・ビーチャム・コーポレイション | Il−8受容体拮抗剤 |
US5780483A (en) * | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6005008A (en) * | 1996-02-16 | 1999-12-21 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
US6262113B1 (en) | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
US6211373B1 (en) | 1996-03-20 | 2001-04-03 | Smithkline Beecham Corporation | Phenyl urea antagonists of the IL-8 receptor |
BR9708735A (pt) * | 1996-04-23 | 1999-08-03 | Vertex Pharma | Derivados de uréia como inibidores da enzina impdh |
EP0906273B1 (en) | 1996-05-24 | 2002-10-16 | Neurosearch A/S | Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers |
PL330849A1 (en) | 1996-06-27 | 1999-06-07 | Smithkline Beecham Corp | Antagonists of il-8 receptors |
AU3409197A (en) * | 1996-06-27 | 1998-01-14 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
JP2000515554A (ja) | 1996-08-06 | 2000-11-21 | スミスクライン・ビーチャム・コーポレイション | Il―8受容体アンタゴニスト |
JP2001523220A (ja) * | 1996-08-06 | 2001-11-20 | スミスクライン・ビーチャム・コーポレイション | Il―8受容体アンタゴニスト |
DK0966465T3 (da) | 1997-03-14 | 2003-10-20 | Vertex Pharma | Inhibitorer af IMPDH-enzymer |
US6696475B2 (en) | 1997-04-22 | 2004-02-24 | Neurosearch A/S | Substituted phenyl derivatives, their preparation and use |
US6187799B1 (en) * | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
US6344476B1 (en) | 1997-05-23 | 2002-02-05 | Bayer Corporation | Inhibition of p38 kinase activity by aryl ureas |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
DK1042305T3 (da) * | 1997-12-22 | 2005-09-19 | Bayer Pharmaceuticals Corp | Inhibering af p38-kinase ved anvendelse af symmetriske og asymmetriske diphenylurinstoffer |
US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
US7329670B1 (en) * | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
IL141479A0 (en) * | 1998-10-22 | 2002-03-10 | Neurosearch As | Substituted phenyl derivatives, their preparation and use |
US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
RU2319693C9 (ru) * | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE556713T1 (de) | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
UY26207A1 (es) * | 1999-06-16 | 2000-12-29 | Smithkline Beecham Corp | Antagonistas de los receptores de la il-8. |
ATE248835T1 (de) | 1999-06-25 | 2003-09-15 | Vertex Pharma | Prodrugs von impdh-inhibierenden carbamaten |
CA2383086A1 (en) | 1999-09-08 | 2001-03-15 | Joseph P. Steiner | Non-peptidic cyclophilin binding compounds and their use |
ATE485266T1 (de) * | 2000-08-10 | 2010-11-15 | Mitsubishi Tanabe Pharma Corp | 3-substituierte harnstoffderivate und deren medizinische verwendung |
US6894063B2 (en) | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
CN1482912A (zh) * | 2000-12-21 | 2004-03-17 | ���鹫˾ | 杂芳基脲神经肽yy5受体拮抗剂 |
US6946476B2 (en) | 2000-12-21 | 2005-09-20 | Schering Corporation | Heteroaryl urea neuropeptide Y Y5 receptor antagonists |
US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
CA2435829A1 (en) | 2001-01-25 | 2002-08-01 | Guilford Pharmaceuticals Inc. | Trisubstituted carbocyclic cyclophilin binding compounds and their use |
WO2002070467A1 (en) | 2001-02-26 | 2002-09-12 | 4Sc Ag | Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments |
DE10109204A1 (de) * | 2001-02-26 | 2002-09-19 | 4Sc Ag | Verbindungen zur Behandlung von Protozoen-Erkrankungen |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
CN1911913A (zh) | 2001-07-26 | 2007-02-14 | 先灵公司 | 取代脲类神经肽y y5受体拮抗剂 |
DE10139416A1 (de) * | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DK1450799T5 (da) * | 2001-12-03 | 2007-09-17 | Bayer Pharmaceuticals Corp | Arulurinstofforbindelser sammen med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere |
CN100506807C (zh) * | 2001-12-21 | 2009-07-01 | 诺沃挪第克公司 | 作为gk活化剂的酰胺衍生物 |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
CN1318404C (zh) * | 2002-02-11 | 2007-05-30 | 拜耳制药公司 | 作为激酶抑制剂的芳基脲类化合物 |
AU2003209119A1 (en) * | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
US20040023961A1 (en) * | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
EP2471533A1 (en) * | 2002-06-27 | 2012-07-04 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US7157472B2 (en) | 2002-07-02 | 2007-01-02 | Schering Corporation | Neuropeptide Y Y5 receptor antagonists |
US7056925B2 (en) * | 2002-08-13 | 2006-06-06 | Abbott Laboratories | Urea kinase inhibitors |
JP4244288B2 (ja) * | 2002-08-29 | 2009-03-25 | フジノン株式会社 | 3群ズームレンズ |
MY143477A (en) * | 2002-10-29 | 2011-05-31 | Smithkline Beecham Corp | Il-8 receptor antagonists |
CN1714076A (zh) * | 2002-11-21 | 2005-12-28 | 神经研究公司 | 芳基脲基衍生物及其医药用途 |
US20060229335A1 (en) * | 2002-12-24 | 2006-10-12 | Bradley Teegarden | Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a |
JP4613157B2 (ja) * | 2003-01-14 | 2011-01-12 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
PT1626714E (pt) * | 2003-05-20 | 2007-08-24 | Bayer Pharmaceuticals Corp | Diarilureias para doenças mediadas por pdgfr |
TW200523253A (en) * | 2003-07-22 | 2005-07-16 | Arena Pharm Inc | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
BR122016015715B8 (pt) | 2003-07-23 | 2021-05-25 | Bayer Healthcare Llc | composições farmacêuticas de metilamida de ácido 4[4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenóxi)-piridina-2-carboxílico |
CA2551037A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
US7829552B2 (en) | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
PT1723128E (pt) * | 2004-01-06 | 2013-02-27 | Novo Nordisk As | Heteroaril-ureias e o seu uso como activadores da glicoquinase |
US7812176B2 (en) * | 2004-03-23 | 2010-10-12 | Arena Pharmaceuticals, Inc. | Processes for preparing substituted N-aryl-N′-[3-(1H-pyrazol-5-YL) phenyl] ureas and intermediates thereof |
EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
EP2295427A1 (en) * | 2004-04-30 | 2011-03-16 | Bayer HealthCare, LLC | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
PE20061130A1 (es) * | 2004-11-19 | 2007-01-05 | Arena Pharm Inc | Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a |
AP2007003979A0 (en) * | 2004-11-23 | 2007-06-30 | Warner Lambert Co | 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia |
WO2006060762A2 (en) * | 2004-12-03 | 2006-06-08 | Arena Pharmaceuticals, Inc. | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
CA2594563A1 (en) * | 2005-01-19 | 2006-07-27 | Arena Pharmaceuticals, Inc. | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy |
AU2006253312B2 (en) | 2005-05-30 | 2011-08-18 | Msd K.K. | Novel piperidine derivative |
EP1904438B1 (en) * | 2005-07-08 | 2012-02-29 | Novo Nordisk A/S | Dicycloalkylcarbamoyl ureas as glucokinase activators |
WO2007006814A1 (en) * | 2005-07-14 | 2007-01-18 | Novo Nordisk A/S | Urea glucokinase activators |
JPWO2007018248A1 (ja) | 2005-08-10 | 2009-02-19 | 萬有製薬株式会社 | ピリドン化合物 |
DE602006017712D1 (de) | 2005-08-24 | 2010-12-02 | Banyu Pharma Co Ltd | Phenylpyridonderivat |
US9296697B2 (en) | 2005-08-24 | 2016-03-29 | Abbott Laboratories | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors |
CA2621470A1 (en) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | Bicyclic aromatic substituted pyridone derivative |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
RU2008119687A (ru) | 2005-10-21 | 2009-11-27 | Новартис АГ (CH) | Комбинации органических соединений |
US8163770B2 (en) | 2005-10-27 | 2012-04-24 | Msd. K. K. | Benzoxathiin derivative |
NZ568292A (en) | 2005-11-10 | 2011-08-26 | Msd Kk | Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
WO2007124423A2 (en) * | 2006-04-21 | 2007-11-01 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
AU2007240365B2 (en) * | 2006-04-21 | 2011-12-15 | Glaxosmithkline Llc | IL-8 receptor antagonists |
BRPI0712030A2 (pt) | 2006-05-18 | 2012-01-03 | Arena Pharm Inc | formas cristalinas e processos para preparaÇço de fenil-pirazàis éteis como moduladores dos receptores de serotonina 5-h-t2a |
US8148417B2 (en) * | 2006-05-18 | 2012-04-03 | Arena Pharmaceuticals, Inc. | Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
AU2007254244C1 (en) | 2006-05-18 | 2014-07-31 | Arena Pharmaceuticals, Inc. | 3-pyrazolyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
TW200817006A (en) * | 2006-06-23 | 2008-04-16 | Smithkline Beecham Corp | IL-8 receptor antagonist |
EP2066642A1 (en) * | 2006-09-25 | 2009-06-10 | Arete Therapeutics, INC. | Soluble epoxide hydrolase inhibitors |
CN101516838A (zh) * | 2006-09-28 | 2009-08-26 | 亚瑞特医疗公司 | 可溶性环氧化物水解酶抑制剂 |
US20090247560A1 (en) | 2006-09-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
TWI415845B (zh) * | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物 |
WO2008045564A2 (en) * | 2006-10-12 | 2008-04-17 | Epix Delaware, Inc. | Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor |
WO2008051875A2 (en) * | 2006-10-20 | 2008-05-02 | Arete Therapeutics, Inc. | Adamantylurea compounds as soluble epoxide hydrolase inhibitors |
JP5498168B2 (ja) | 2006-12-01 | 2014-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | アテローム性動脈硬化および循環器疾患の治療のためのcetp阻害剤としてのn−((3−ベンジル)−2,2−(ビス−フェニル)−プロパン−1−アミン誘導体 |
WO2008074756A1 (en) * | 2006-12-18 | 2008-06-26 | Neurosearch A/S | Novel biphenyl thio-urea derivatives useful as potassium channel modulators |
EP2118083A1 (en) * | 2007-01-09 | 2009-11-18 | Novo Nordisk A/S | Urea glucokinase activators |
WO2008084044A1 (en) | 2007-01-11 | 2008-07-17 | Novo Nordisk A/S | Urea glucokinase activators |
EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
JP5393677B2 (ja) | 2007-08-15 | 2014-01-22 | アリーナ ファーマシューティカルズ, インコーポレイテッド | 5−HT2Aセロトニン受容体に関連した障害の治療のための5−HT2Aセロトニン受容体のモジュレーターとしてのイミダゾ[1,2−a]ピリジン誘導体 |
WO2009035951A2 (en) * | 2007-09-11 | 2009-03-19 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
US20100331298A1 (en) * | 2007-12-10 | 2010-12-30 | Cytopathfinder, Inc. | Carboxamide Compounds and Their Use |
AU2008335135A1 (en) | 2007-12-11 | 2009-06-18 | Cytopathfinder, Inc. | Carboxamide compounds and their use as chemokine receptor agonists |
US20110015181A1 (en) | 2008-03-06 | 2011-01-20 | Makoto Ando | Alkylaminopyridine derivative |
JPWO2009119726A1 (ja) | 2008-03-28 | 2011-07-28 | Msd株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
EP3239170B1 (en) | 2008-06-04 | 2019-03-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009261248A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
AU2009277736A1 (en) | 2008-07-30 | 2010-02-04 | Banyu Pharmaceutical Co., Ltd. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
PT2364142T (pt) * | 2008-10-28 | 2018-04-23 | Arena Pharm Inc | Composições de um modulador do recetor da serotonina 5-ht2a para o tratamento de distúrbios com ele relacionados |
WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US20120046364A1 (en) | 2009-02-10 | 2012-02-23 | Metabasis Therapeutics, Inc. | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use |
CA2755394C (en) | 2009-03-13 | 2021-10-19 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
SG10201403696UA (en) | 2009-06-29 | 2014-10-30 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
ES2594402T3 (es) | 2009-10-21 | 2016-12-20 | Agios Pharmaceuticals, Inc. | Métodos y composiciones para trastornos relacionados con la proliferación celular |
US8980891B2 (en) | 2009-12-18 | 2015-03-17 | Arena Pharmaceuticals, Inc. | Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto |
JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
WO2011145022A1 (en) | 2010-05-21 | 2011-11-24 | Pfizer Inc. | 2-phenyl benzoylamides |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CN105001219A (zh) | 2011-02-25 | 2015-10-28 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
EP2680874A2 (en) | 2011-03-04 | 2014-01-08 | Pfizer Inc | Edn3-like peptides and uses thereof |
RS57342B1 (sr) | 2011-05-03 | 2018-08-31 | Agios Pharmaceuticals Inc | Aktivatori piruvat kinaze za upotrebu u terapiji |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN103159686A (zh) * | 2011-12-09 | 2013-06-19 | 天津市国际生物医药联合研究院 | 一种hiv-1蛋白酶的脲类抑制剂 |
US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
AU2013331626B2 (en) * | 2012-10-15 | 2018-08-02 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗糖尿病二環式化合物 |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014170786A1 (en) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
EP3004138B1 (en) | 2013-06-05 | 2024-03-13 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
AU2014287121B2 (en) | 2013-07-11 | 2018-11-15 | Agios Pharmaceuticals, Inc. | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
GB201404372D0 (en) | 2014-03-12 | 2014-04-23 | Univ Warwick | Assay and treatment |
CA2942072C (en) | 2014-03-14 | 2022-07-26 | Agios Pharmaceuticals, Inc. | Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide |
CN113121450A (zh) | 2014-08-29 | 2021-07-16 | Tes制药有限责任公司 | α-氨基-β-羧基粘康酸半醛脱羧酶抑制剂 |
WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
ES2959690T3 (es) | 2015-06-11 | 2024-02-27 | Agios Pharmaceuticals Inc | Procedimientos de uso de activadores de piruvato cinasa |
WO2016201373A1 (en) | 2015-06-12 | 2016-12-15 | Axovant Sciences Ltd. | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
RU2018103338A (ru) | 2015-07-15 | 2019-08-15 | Аксовант Сайенсиз Гмбх | Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием |
US10653710B2 (en) | 2015-10-15 | 2020-05-19 | Agios Pharmaceuticals, Inc. | Combination therapy for treating malignancies |
PT3362065T (pt) | 2015-10-15 | 2024-06-21 | Servier Lab | Terapia de combinação compreendendo ivosidenib, citarabina e daunorubicina ou idarubicina para o tratamento de leucemia mielóide aguda |
CA3038185A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
AU2019287437A1 (en) | 2018-06-12 | 2020-09-10 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
KR20210111248A (ko) | 2018-11-20 | 2021-09-10 | 테스 파마 에스.알.엘. | α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제 |
JOP20210193A1 (ar) | 2019-01-18 | 2023-01-30 | Astrazeneca Ab | مثبطات pcsk9 وطرق استخدامها |
CZ2020559A3 (cs) * | 2020-10-13 | 2022-04-27 | Ústav experimentální botaniky AV ČR, v. v. i. | Látky pro rostlinné biotechnologie na bázi 1-fenyl-3-yl-močoviny, přípravky je obsahující a jejich použití |
CN115804844B (zh) * | 2022-09-26 | 2024-05-10 | 郑州大学 | 靶向抑制pak4的抑制剂在制备肿瘤防治药剂中的应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE924864C (de) * | 1950-11-12 | 1955-04-21 | Hoechst Ag | Verfahren zur Herstellung von Thioharnstoffabkoemmlingen |
DE859151C (de) * | 1951-03-09 | 1952-12-11 | Gruenenthal Chemie | Verfahren zur Herstellung des symm. Di-[2-oxy-carboxyphenyl-(4)]-thioharnstoffs |
FR1063842A (fr) * | 1951-05-28 | 1954-05-07 | Ciba Geigy | Procédé de préparation de nouvelles bis-phényl-thiourées |
FR1067900A (fr) * | 1951-07-20 | 1954-06-21 | Ciba Geigy | Procédé pour la préparation de nouvelles bis-phényl-thiourées |
FR1073588A (fr) * | 1952-01-28 | 1954-09-27 | Ciba Geigy | Procédé pour la préparation de nouvelles diphényl-thiourées substituées |
FR1078457A (fr) * | 1952-01-31 | 1954-11-18 | Ciba Geigy | Procédé de préparation de nouvelles diphényl-thiourées substituées |
US2688039A (en) * | 1952-02-08 | 1954-08-31 | Ciba Pharm Prod Inc | Halogen-containing di-(substituted phenyl)-thioureas |
FR1080728A (fr) * | 1952-05-02 | 1954-12-13 | Ciba Geigy | Procédé de préparation de nouvelles diphénylthiourées substituées |
DE962699C (de) * | 1953-04-26 | 1957-04-25 | Schering Ag | Verfahren zur Herstellung choleretisch wirksamer N-Acylderivate der 2, 4, 6-Trijod-3-amino-benzoesaeure |
US2745874A (en) * | 1953-06-18 | 1956-05-15 | Geigy Ag J R | Insecticidal derivatives of diphenyl urea |
CH322815A (de) * | 1954-03-09 | 1957-06-30 | Wander Ag Dr A | Verfahren zur Darstellung von N,N'-(4,4'-Dicarboxy-3,3'-dioxy)-diphenyl-harnstoff und dessen Salzen |
US2983646A (en) * | 1958-04-10 | 1961-05-09 | Monsanto Chemicals | Anthelmintic compositions containing substituted carbanilides and methods of using same |
NL254871A (xx) * | 1959-08-14 | |||
DE1221638B (de) * | 1960-07-22 | 1966-07-28 | Hoechst Ag | Verfahren zur Herstellung von Thioharnstoffen |
US3340145A (en) * | 1961-04-21 | 1967-09-05 | Ciba Geigy Corp | Carbanilide compositions and methods of using same |
FR2104M (fr) * | 1962-01-26 | 1963-10-28 | Madan Ag | Thiocarbanilides a propriétés anti inflammatoires et antifongiques. |
FR3361M (fr) * | 1962-04-02 | 1965-06-08 | Ciba Geigy | Nouveau médicament anthelmintique. |
US3200035A (en) * | 1962-06-01 | 1965-08-10 | Ciba Ltd | Treatment of synthetic products, especially synthetic fibers |
GB969808A (en) * | 1962-06-08 | 1964-09-16 | Boots Pure Drug Co Ltd | Anthelmintic compositions and compounds |
GB1055741A (en) * | 1963-07-12 | 1967-01-18 | Ici Ltd | Pharmaceutical compositions comprising substituted urea derivatives |
GB1059034A (en) * | 1964-01-16 | 1967-02-15 | Ici Ltd | Urea derivatives |
US3335142A (en) * | 1965-07-07 | 1967-08-08 | American Cyanamid Co | Process for the preparation of n, n'-disubstituted ureas |
SE370866B (xx) * | 1968-03-21 | 1974-11-04 | Ciba Geigy Ag | |
GB1219698A (en) * | 1969-10-22 | 1971-01-20 | Givaudan & Cie Sa | Substituted carbanilides and their use |
US3856952A (en) * | 1973-03-01 | 1974-12-24 | Pennwalt Corp | Synergistic antimicrobial compositions employing certain n-(phenyl-carbamyl)amino-benzene sulfonyl flourides |
DE2311020A1 (de) * | 1973-03-06 | 1974-09-12 | Pfizer | Substituierte benzoesaeuren und arzneimittel |
US3860645A (en) * | 1973-05-23 | 1975-01-14 | Givaudan Corp | Bacteriostatic substituted carbanilides |
US3903130A (en) * | 1974-05-03 | 1975-09-02 | Stauffer Chemical Co | 1-Trifluormethylphenyl-3-dicyanophenyl urea |
US4011340A (en) * | 1975-05-08 | 1977-03-08 | Sandoz, Inc. | Hypolipidemic bis(pivaloylbenzyl) ureas |
-
1979
- 1979-07-14 DE DE19792928485 patent/DE2928485A1/de not_active Withdrawn
-
1980
- 1980-06-30 NO NO801965A patent/NO151362C/no unknown
- 1980-07-02 EP EP80103765A patent/EP0022958A1/de not_active Withdrawn
- 1980-07-08 AU AU60194/80A patent/AU544252B2/en not_active Expired - Fee Related
- 1980-07-11 ZA ZA00804180A patent/ZA804180B/xx unknown
- 1980-07-11 ES ES493327A patent/ES493327A0/es active Granted
- 1980-07-11 IL IL60555A patent/IL60555A0/xx unknown
- 1980-07-11 JP JP9410880A patent/JPS5616411A/ja active Pending
- 1980-07-11 DK DK302480A patent/DK302480A/da not_active Application Discontinuation
-
1981
- 1981-12-17 US US06/331,712 patent/US4405644A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DK302480A (da) | 1981-01-15 |
AU6019480A (en) | 1981-01-15 |
NO151362C (no) | 1985-03-27 |
US4405644A (en) | 1983-09-20 |
NO801965L (no) | 1981-01-15 |
ES8105292A1 (es) | 1981-05-16 |
NO151362B (no) | 1984-12-17 |
ES493327A0 (es) | 1981-05-16 |
JPS5616411A (en) | 1981-02-17 |
IL60555A0 (en) | 1980-09-16 |
EP0022958A1 (de) | 1981-01-28 |
DE2928485A1 (de) | 1981-01-29 |
AU544252B2 (en) | 1985-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA804180B (en) | Medicaments for the treatment of disorders in lipometabolism and their use | |
ZA791728B (en) | Cerebral therapeutic agent and its use | |
JPS5643217A (en) | Water drug for external application for trauma treatment and manufacture thereof | |
JPS5692816A (en) | Prescription of long controlled effect belnded medicine and its composition | |
GB2013495A (en) | Therapeutic method for the treatment of hyperlipodaemias and hyperlipoproteinaemias | |
EP0204597A3 (en) | Use of alfuzosine in the treatment of urinary affections | |
ZW19680A1 (en) | Preparations for the treatment of theileriosis and their use | |
JPS5615250A (en) | Aminoether type oxide* its manufacture and therapeutic use | |
DE3062981D1 (en) | Alkyl-urea derivatives for the treatment of lipometabolic diseases; process for their preparation, their use in medicaments for the treatment of lipometabolic disorders, medicaments containing them, process for the preparation of the medicaments, and some alkyl-urea derivatives | |
HK36693A (en) | Use of ketone derivatives in the treatment of cognitive disorders | |
HU178841B (en) | Cattle-leader for the prophylactic or therapeutic treatment of cattle | |
JPS5622716A (en) | Hair treatment product and its manufacture | |
GB2071091B (en) | Acyl-derivatives of carnitine and the therapeutic use thereof | |
ZA796882B (en) | Use of glycerylphosphoryl derivatives in the therapy of dislipaemia,hepatitis and like pathological conditions and pharmaceutical compositions therefor | |
GB2098478B (en) | Propioibacteria preparations for use in the treatment of tumours | |
AU530790B2 (en) | Triazinones and their use in treating gastrointestinal disorders | |
IL59764A0 (en) | Drug on the basis of dihydroergo-toxine and procedure for its manufacture | |
GB1546034A (en) | Therapeutic compositions and the use thereof | |
PH16250A (en) | Pharmaceutical composition of therapeutic value in the treatment of some shock conditions | |
DE3362340D1 (en) | A pharmaceutical composition and the use thereof for the treatment of inflammation | |
DE3264378D1 (en) | Medicaments for the treatment of obesity and hyperlipoidemia | |
EG14024A (en) | Pharmaceutical compositions and their use in the profyloxis and or treatment of certain diseases | |
GB2048250B (en) | 2-amino-6-aryl-4-pyrimidinols and their pharmaceutical uses | |
EP0059346A3 (en) | Therapeutic agent and the use thereof | |
JPS5543094A (en) | 3*44dihydroisoquinolines*their manufacture and their medical use |